Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 39-5 - October 28, 2025
- Latest edition
- Editors: Jennifer R. Brown︎, Matthew S. Davids
- Language: English
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jennifer R. Brown and Matthew S. Davids bring their considerable expertise to the topic of Chronic Lymphocyt… Read more
Purchase options
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jennifer R. Brown and Matthew S. Davids bring their considerable expertise to the topic of Chronic Lymphocytic Leukemia. Top experts provide in-depth perspectives on CLL, including basic biology, frontline and relapsed refractory treatments, mechanisms of resistance to targeted therapies, Richter’s transformation, and some of the common complications of the disease stemming from immune dysfunction—offering a state-of-the-art overview of the field to help optimize the care of patients with CLL.
- Contains 13 relevant, practice-oriented topics including autonomous B cell receptor signaling; triple drug combinations; management of relapsed/refractory CLL; resistance to BTK inhibitors; immune therapy for CLL; and more
- Provides in-depth clinical reviews on chronic lymphocytic leukemia, offering actionable insights for clinical practice
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews
Hematology, oncology
Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia
The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework
for Understanding Biological and Clinical Heterogeneity
Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton’s
Tyrosine Kinase Inhibitors: A Comprehensive Overview
First-line Therapy: Time-Limited Venetoclax Doublet Therapy
Triplet Therapies in Chronic Lymphocytic Leukemia
Measurable/Minimal Residual Disease: What Method and What Cut-Off?
Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Resistance to Bruton Tyrosine Kinase Inhibitors
Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic
Leukemia
Immunotherapy in Chronic Lymphocytic Leukemia
Advances in the Understanding of Richter Transformation
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Understanding and Managing Infectious Complications in Chronic Lymphocytic
Leukemia
The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework
for Understanding Biological and Clinical Heterogeneity
Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton’s
Tyrosine Kinase Inhibitors: A Comprehensive Overview
First-line Therapy: Time-Limited Venetoclax Doublet Therapy
Triplet Therapies in Chronic Lymphocytic Leukemia
Measurable/Minimal Residual Disease: What Method and What Cut-Off?
Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Resistance to Bruton Tyrosine Kinase Inhibitors
Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic
Leukemia
Immunotherapy in Chronic Lymphocytic Leukemia
Advances in the Understanding of Richter Transformation
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Understanding and Managing Infectious Complications in Chronic Lymphocytic
Leukemia
- Edition: 1
- Latest edition
- Volume: 39-5
- Published: October 28, 2025
- Language: English
JB
Jennifer R. Brown︎
Affiliations and expertise
Professor of Medicine, Harvard Medical School,Director of CLL Center, Dana-Farber Cancer Institute, USAMD
Matthew S. Davids
Affiliations and expertise
Associate Professor of Medicine | Harvard Medical School Leader Lymphoma Program | Dana-Farber/Harvard Cancer Center Director of Clinical Research | Division of Lymphoma Dana-Farber Cancer Institute Boston, MA, USA